|
|
|
|
Successful viral vector scale‑up depends on early process design, predictive models, and execution strategies that anticipate GMP realities rather than simply increasing production volume.
|
|
|
|
|
Early CMC and expression system decisions in recombinant protein development shape quality, cost, and manufacturability, while cross-functional collaboration helps avoid bottlenecks when scaling to commercial production.
|
|
|
|
|
Adenoviruses are being reimagined as powerful tools for oncolytic cancer therapy, using their immunogenicity, tumor selectivity, and synergy with immunotherapy to drive new clinical progress.
|
|
|
|
|
Integrated analytical capabilities within a CDMO are increasingly preferred to overcome challenges associated with outsourcing analysis in biopharma development and manufacturing.
|
|
|
|
|
Discover how to effectively navigate the transition to GMP, ensuring your project meets stringent requirements while streamlining development and minimizing risk.
|
|
|
|
|
Optimizing fixed-bed bioreactor parameters streamlines the large-scale production of adenoviral vectors, overcoming traditional manufacturing bottlenecks to reliably meet clinical and commercial demands for modern gene therapy and vaccine applications.
|
|
|
|
|
|
|
What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.
|
|
|
|
|
|
|
With decades of hands-on experience in microbial fermentation and a commitment to scientific precision, we’ve built a trusted foundation that continues to drive successful outcomes for our partners.
|
|
|
|
|
|
|